Farms.com Home   News

Richardson Canola Plant Workers Reject Contract Offer

Workers at the Richardson canola processing plant in Lethbridge have rejected the company’s latest contract offer and are now seeking mediation.

A statement this week from United Food and Commercial Workers (UFCW) Local 401, which represents about 140 plant employees, said workers rejected the proposed pact by a vote of 79%, with the union bargaining committee now preparing its next steps – the first of which is applying for mediation. Furthermore, the union said it is looking to return to the bargaining table to see if the company will improve its offer.

“Like a decisive strike vote, a rejected ratification vote often inspires employers to look more seriously into their profits,” the union said. “No matter how they rationalize it, they know a strike will cost them money.”

Workers voted on what was described as the company’s ‘best and final offer’ – which included improvements to wages, benefits and pension -on Dec. 16 -17.

A strike vote has not yet taken place.

Richardson’s Lethbridge plant has the capacity to process up to 700,000 tonnes of canola per year, following a $120 million expansion in 2017.

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.